Department of Pathology
  Brigham and Women's Hospital
  A teaching Affliate of Harvard Medical School
Login Skip Navigation Links
  Skip Navigation Links
HomeExpand Home


Submit new announcement
Jane E. Brock, M.B.B.S.,Ph.D.

Assistant Professor in Pathology, Harvard Medical School
Medical Director of Surgical Pathology Grossing Room

Academic Activities:
Dr. Brock covers both general surgical pathology and the subspecialty breast pathology service including institutional consults for Dana-Farber Cancer Institute and diagnostic breast pathology consults. She evaluates pathology for breast cancer clinical trials running at the Dana-Farber Breast Cancer Center and focuses her academic research on pathologic prognostic factors in breast cancer. She has published in areas including ER and HER2/neu status evaluation and prognostic factors in DCIS and microinvasive breast carcinomas.
75 Francis Street
Boston,MA 02115
Education and Training:

College 1990 - 1993 : Oxford University: Pre-Clinical Medicine and B.A. in Physiology.
Graduate School 1993 - 1996 : Department of Anatomy and Developmental Biology, University College London, UK: Ph.D. in Tissue Repair in Embryos.
Medical School 1996 - 1999 : UCH & Middlesex Hospitals, University of London, UK: M.B. B.S.
Internship 1999 - 2000 : UCH, Middlesex, & Harrogate Hospitals, UK: PRHO in Medicine & Surgery.
Residency 2000 - 2002 : North West Thames Pediatric Training Rotation, London, UK: SHO in Pediatrics and Neonatal Intensive Care.
Residency 2003 - 2007 : Brigham & Women's Hospital, Boston, MA: Anatomic Pathology Residency.
Fellowship 2007 - 2008 : Brigham & Women's Hospital, Boston, MA: Breast Pathology.

Clinical Specialties:
  • Breast Pathology
  • Anatomic Pathology
Research Interests:
  • Breast Cancer
  1. Brock, JE, Hornick JL, Richardson AL, Dillon DA, Lester SC. A comparison of Estrogen Receptor SP1 and 1D5 monoclonal antibodies in routine clinical use reveals similar staining results. Am J Clin Pathol. 2009 Sep;132(3):396-401.
  2. Tung N, Miron A, Schnitt SJ, Gautam S, Fetten K, Kaplan J, Yassin Y, Buraimoh A, Kim JY, Szasz AM, Tian R, Wang ZC, Collins LC, Brock J, Krag K, Legare RD, Sgroi D, Ryan PD, Silver DP, Garber JE, Richardson AL. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. Breast Cancer Res. 2010;12(6):R95.
  3. Manion E, Hornick JL, Lester SC, Brock JE. A comparison of equivocal immunohistochemical results with anti-HER2/neu antibodies A0485 and SP3 with corresponding FISH results in routine clinical practice. Am J Clin Pathol. 2011 June;135(6):845-851.
  4. Halasz LM, Sreedhara M; Chen YH, Bellon JR, Punglia RS, Wong JS, Harris JR, Brock JE. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma-in-situ. Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):e581-6.
  5. Liao GS, Dominici L, Brock J, Iglehart JD, Lotfi P, Meyer J, Pandalai P, Golshan M. Large needle core biopsy of atypical ductal hyperplasia: results of surgical excision. Breast J. 2012 103 Letter to the Editor.
  6. Margalit DN, Sreedhara M, Chen YH, Catalano PJ, Nguyen PL, Golshan M, Overmoyer BA, Harris JR, Brock JE. Microinvasive Breast Cancer: ER, PR, and HER2/neu status and clinical outcomes after breast-conserving therapy or mastectomy. Ann Surg Onc. 2013; 20(3):811-8187.
  7. Reisenbichler ES, Lester SC, Richardson AR, Dillon DA Ly A, Brock JE; Interobserver concordance in implementing the 2010 ASCO/CAP recommendations for reporting ER in breast carcinomas; a demonstration of the difficulties of consistently reporting low levels of ER expression by manual quantification. Am. J. Clin. Pathol 2013 Oct; 140(4):487-94
  8. Kansal KJ, Dominici LS, Tolaney SM, Isakoff SJ, Smith BL, Jiang W, Brock JE, Winer, EP, Krop IE, Golshan M. Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction. Breast Cancer Res Treat. 2013 141(2):255-9
  9. Russo AL, Arvold ND, Neimerko A, Wong N, Wong JS, Bellon JR, Punglia RS, Golshan M, Troyan SL, Brock JE, Harris JR. Margin status and the risk of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy. Breast Cancer Res Treat. 2013 140(2):353-61
  10. Kluk MJ, Ashworth T, Wang H, Knoechel B, Mason EF, Morgan EA, Dorfman D, Pinkus G, Weigert O, Hornick JL, Chirieac L, Hirsch M, Oh DJ, South AP, Leigh IM, Pourreyron C, Cassidy AJ, DeAngelo DJ, Weinstock DM, Krop IE, Dillon D, Brock JE, Lazar AJ, Peto M, Cho RJ, Stoeck A, Haines B, Sathayanrayanan S, Rodig S, Aster JC. Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. PLOS 2013 8(6):e67306.
  11. Tolaney SM, Heong J, Guo H, Brock J, Morganstern D, Come SE, Golshan M, Bellon J, Winer, EP, Krop IE. A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer. Cancer Medicine 2014 Jan 27 Cancer Medicine 2014 Apr;3(2):293-9
<September 2019>

<Sunday, September 15, 2019>
Copyright 2008 - 2019, BWH Pathology, All rights reserved.